Saturday, June 27, 2009

Lisinopril Ipca




Lisinopril Ipca may be available in the countries listed below.


Ingredient matches for Lisinopril Ipca



Lisinopril

Lisinopril dihydrate (a derivative of Lisinopril) is reported as an ingredient of Lisinopril Ipca in the following countries:


  • Slovakia

International Drug Name Search

Urisue




Urisue may be available in the countries listed below.


Ingredient matches for Urisue



Benzbromarone

Benzbromarone is reported as an ingredient of Urisue in the following countries:


  • Taiwan

International Drug Name Search

Friday, June 26, 2009

Megalac Almasilat




Megalac Almasilat may be available in the countries listed below.


Ingredient matches for Megalac Almasilat



Almasilate

Almasilate is reported as an ingredient of Megalac Almasilat in the following countries:


  • Germany

International Drug Name Search

Thursday, June 25, 2009

Wormgranulaat




Wormgranulaat may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Wormgranulaat



Fenbendazole

Fenbendazole is reported as an ingredient of Wormgranulaat in the following countries:


  • Netherlands

International Drug Name Search

Tuesday, June 23, 2009

Paspertin




Paspertin may be available in the countries listed below.


Ingredient matches for Paspertin



Metoclopramide

Metoclopramide hydrochloride (a derivative of Metoclopramide) is reported as an ingredient of Paspertin in the following countries:


  • Austria

  • Germany

  • Switzerland

International Drug Name Search

NasenSpray-ratiopharm




NasenSpray-ratiopharm may be available in the countries listed below.


Ingredient matches for NasenSpray-ratiopharm



Xylometazoline

Xylometazoline hydrochloride (a derivative of Xylometazoline) is reported as an ingredient of NasenSpray-ratiopharm in the following countries:


  • Luxembourg

International Drug Name Search

Met




Met may be available in the countries listed below.


Ingredient matches for Met



Metformin

Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Met in the following countries:


  • Bangladesh

  • Germany

  • Peru

International Drug Name Search

Sunday, June 21, 2009

Tamsulosina Sandoz




Tamsulosina Sandoz may be available in the countries listed below.


Ingredient matches for Tamsulosina Sandoz



Tamsulosin

Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsulosina Sandoz in the following countries:


  • Italy

  • Spain

International Drug Name Search

Friday, June 19, 2009

Ital-Ultra




Ital-Ultra may be available in the countries listed below.


Ingredient matches for Ital-Ultra



Ambroxol

Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Ital-Ultra in the following countries:


  • Mexico

International Drug Name Search

Monday, June 15, 2009

Spirobeta




Spirobeta may be available in the countries listed below.


Ingredient matches for Spirobeta



Spironolactone

Spironolactone is reported as an ingredient of Spirobeta in the following countries:


  • Germany

International Drug Name Search

Sunday, June 14, 2009

Progesterona




Progesterona may be available in the countries listed below.


Ingredient matches for Progesterona



Progesterone

Progesterone is reported as an ingredient of Progesterona in the following countries:


  • Chile

International Drug Name Search

Tuesday, June 9, 2009

Actiq


Actiq is a brand name of fentanyl, approved by the FDA in the following formulation(s):


ACTIQ (fentanyl citrate - troche/lozenge; transmucosal)



  • Manufacturer: CEPHALON

    Approval date: November 4, 1998

    Strength(s): EQ 0.2MG BASE [AB], EQ 0.4MG BASE [RLD][AB], EQ 0.6MG BASE [AB], EQ 0.8MG BASE [AB], EQ 1.2MG BASE [AB], EQ 1.6MG BASE [AB]

Has a generic version of Actiq been approved?


Yes. The following products are equivalent to Actiq:


fentanyl citrate troche/lozenge; transmucosal



  • Manufacturer: BARR

    Approval date: October 30, 2009

    Strength(s): EQ 0.2MG BASE [AB], EQ 0.4MG BASE [AB], EQ 0.6MG BASE [AB], EQ 0.8MG BASE [AB], EQ 1.2MG BASE [AB], EQ 1.6MG BASE [AB]


  • Manufacturer: MALLINCKRODT

    Approval date: October 30, 2009

    Strength(s): EQ 0.2MG BASE [AB], EQ 0.4MG BASE [AB], EQ 0.6MG BASE [AB], EQ 0.8MG BASE [AB], EQ 1.2MG BASE [AB], EQ 1.6MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Actiq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Actiq.

See also...

  • Actiq Consumer Information (Drugs.com)
  • Actiq Lozenge Consumer Information (Wolters Kluwer)
  • Actiq oral transmucosal Consumer Information (Cerner Multum)
  • Actiq Advanced Consumer Information (Micromedex)
  • Fentanyl Consumer Information (Drugs.com)
  • Fentanyl Consumer Information (Wolters Kluwer)
  • Fentanyl Lozenge Consumer Information (Wolters Kluwer)
  • Fentanyl Patch Consumer Information (Wolters Kluwer)
  • Fentanyl Soluble Film Consumer Information (Wolters Kluwer)
  • Fentanyl Spray Consumer Information (Wolters Kluwer)
  • Fentanyl Tablet Consumer Information (Wolters Kluwer)
  • Fentanyl buccal Consumer Information (Cerner Multum)
  • Fentanyl citrate oral transmucosal Consumer Information (Cerner Multum)
  • Fentanyl nasal Consumer Information (Cerner Multum)
  • Fentanyl sublingual Consumer Information (Cerner Multum)
  • Fentanyl transdermal device Consumer Information (Cerner Multum)
  • Fentanyl transdermal skin patch Consumer Information (Cerner Multum)
  • Fentanyl Buccal mucosa, Oromucosal Advanced Consumer Information (Micromedex)
  • Fentanyl Nasal Advanced Consumer Information (Micromedex)
  • Fentanyl Transdermal Advanced Consumer Information (Micromedex)
  • Fentanyl Citrate AHFS DI Monographs (ASHP)

Saturday, June 6, 2009

respiratory syncytial virus immune globulin (RSV IG) injectable


Generic Name: respiratory syncytial virus immune globulin (RSV IG) (injectable) (RES pir tory SIN sih shull VYE rus ih MUNE GLAW byoo lin)

Brand Names: Respigam


What is RSV IG?

Respiratory syncytial virus immune globulin (RSV IG) is a sterilized solution obtained from pooled human blood. It contains the immunoglobulins (or antibodies) to protect against infection from respiratory syncytial virus (RSV), a virus that can cause serious illness in children. Antibodies are substances in the blood that fight infections.


RSV IG is used to help prevent or reduce the severity of lower respiratory tract (lung) disease caused by respiratory syncytial virus in children who are at increased risk.


RSV IG may also be used for purposes other than those listed here.


What is the most important information I should know about RSV IG?


RSV IG is made from human plasma (part of the blood) and may contain infectious agents (e.g., viruses) that can cause disease. Although RSV IG is screened, tested, and treated to reduce the possibility that it carries an infectious agent, it can still potentially transmit disease. Discuss with the doctor the risks and benefits of using RSV IG.


Treatment with immune globulin products such as RSV IG has been associated with the development of kidney problems, sometimes resulting in kidney failure and/or death. Notify the doctor immediately if symptoms such as decreased urination, sudden weight gain, fluid retention or swelling, or shortness of breath occur. These may be signs of kidney problems. Rare cases of aseptic meningitis syndrome (AMS) have been associated with the use of immune globulin products such as RSV IG. Notify the doctor immediately if symptoms such as severe headache, neck stiffness, drowsiness, fever, eye sensitivity to light, painful eye movements, and nausea or vomiting occur. These may be signs of AMS. Stopping treatment with the immune globulin has resulted in resolution of AMS without any lasting problems.

What should I discuss with my healthcare provider before using RSV IG?


Do not use RSV IG without first talking to your doctor if you have

  • kidney disease;




  • diabetes;




  • IgA deficiency; or




  • had a previous allergic reaction to an immune globulin product.



You may not be able to use RSV IG, or you may require a dosage adjustment or special monitoring during treatment.


RSV IG is in the FDA pregnancy category C. This means that it is not known whether it will be harmful to an unborn baby. Do not use RSV IG without first talking to your doctor if you are pregnant or could become pregnant during treatment. It is not known whether RSV IG passes into breast milk. Do not use RSV IG without first talking to your doctor if you are breast-feeding a baby.

How should I take RSV IG?


RSV IG will be administered by intravenous (into a vein) injection by a healthcare provider in a hospital or clinic setting. If RSV IG is being administered at home, your healthcare provider will give you detailed instructions regarding administration.


RSV IG is usually administered once a month during the RSV season. Your healthcare provider will give you detailed instructions on when the medication should be administered.


Your doctor may want to perform monitoring during treatment with RSV IG to monitor progress and side effects.


Your healthcare provider will store RSV IG as directed by the manufacturer. If RSV IG is being stored at home, your healthcare provider will give you storage instructions.


See also: Respiratory syncytial virus immune globulin (RSV IG) dosage (in more detail)

What happens if I miss a dose?


Contact your healthcare provider if a dose of RSV IG is missed.


What happens if I overdose?


Seek emergency medical attention or contact your healthcare provider if an overdose of RSV IG is suspected.

No information is available regarding an overdose of RSV IG.


What should I avoid while taking RSV IG?


Vaccinations that use live strains of the virus (e.g., measles, mumps, and rubella or MMR) given during and for approximately ten months following treatment with RSV IG may not produce the desired response. Additional doses of the vaccine may be necessary to ensure effectiveness.

RSV IG side effects


RSV IG is made from human plasma (part of the blood) and may contain infectious agents (e.g., viruses) that can cause disease. Although RSV IG is screened, tested, and treated to reduce the possibility that it carries an infectious agent, it can still potentially transmit disease. Discuss with the doctor the risks and benefits of using RSV IG.


Treatment with immune globulin products such as RSV IG has been associated with the development of kidney problems, sometimes resulting in kidney failure and/or death. Notify the doctor immediately if symptoms such as decreased urination, sudden weight gain, fluid retention or swelling, or shortness of breath occur. These may be signs of kidney problems. Rare cases of aseptic meningitis syndrome (AMS) have been associated with the use of immune globulin products such as RSV IG. Notify the doctor immediately if symptoms such as severe headache, neck stiffness, drowsiness, fever, eye sensitivity to light, painful eye movements, and nausea or vomiting occur. These may be signs of AMS. Stopping treatment with the immune globulin has resulted in resolution of AMS without any lasting problems. Notify your doctor immediately if a rare but serious allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives) to RSV IG is experienced.

Other less serious side effects may also occur. Upon injection of the medication, some patients may experience the following side effects:



  • fever;




  • vomiting;




  • diarrhea; or




  • rash.



Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.


Respiratory syncytial virus immune globulin (RSV IG) Dosing Information


Usual Pediatric Dose for Respiratory Syncytial Virus:


The infusion should be gradually increased as tolerated by starting with 1.5 mL/kg/hr for 15 minutes followed by 3.6 mL/kg/hr for remainder of infusion. Rate of infusion should not exceed 3.6 mL/kg/hr. It may be necessary to infuse at a slower rate in some patients, especially ill children with BPD.


What other drugs will affect RSV IG?


Vaccinations that use live strains of the virus (e.g., measles, mumps, and rubella or MMR) given during and for approximately ten months following treatment with RSV IG may not produce the desired response. Additional doses of the vaccine may be necessary to ensure effectiveness.

It is not known whether other medications will interact with RSV IG. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including herbal products during treatment with RSV IG.



More respiratory syncytial virus immune globulin (RSV IG) resources


  • Respiratory syncytial virus immune globulin (RSV IG) Side Effects (in more detail)
  • Respiratory syncytial virus immune globulin (RSV IG) Dosage
  • Respiratory syncytial virus immune globulin (RSV IG) Use in Pregnancy & Breastfeeding
  • Respiratory syncytial virus immune globulin (RSV IG) Drug Interactions
  • Respiratory syncytial virus immune globulin (RSV IG) Support Group
  • 0 Reviews for Respiratory syncytial virus immune globulin (RSV IG) - Add your own review/rating


Compare respiratory syncytial virus immune globulin (RSV IG) with other medications


  • Respiratory Syncytial Virus


Where can I get more information?


  • Your pharmacist has additional information about RSV IG written for health professionals that you may read.

What does my medication look like?


RSV IG is available with a prescription under the brand name Respigam. Other brand or generic formulations may also be available. Ask your pharmacist any questions you have about this medication, especially if it is new to you.


See also: respiratory syncytial virus immune globulin (RSV IG) side effects (in more detail)


Wednesday, June 3, 2009

Citalopram beta




Citalopram beta may be available in the countries listed below.


Ingredient matches for Citalopram beta



Citalopram

Citalopram hydrobromide (a derivative of Citalopram) is reported as an ingredient of Citalopram beta in the following countries:


  • Germany

  • Netherlands

International Drug Name Search

Cinfatos




Cinfatos may be available in the countries listed below.


Ingredient matches for Cinfatos



Dextromethorphan

Dextromethorphan hydrobromide (a derivative of Dextromethorphan) is reported as an ingredient of Cinfatos in the following countries:


  • Dominican Republic

  • El Salvador

  • Guatemala

  • Panama

  • Spain

International Drug Name Search